Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Diabetes Metab Syndr ; 15(5): 102240, 2021.
Artículo en Inglés | MEDLINE | ID: covidwho-1347578

RESUMEN

AIMS: To evaluate calculated total plasma osmolality as a marker of outcome prediction, fluid and metabolic balance, thrombotic risk in severe COVID-19 patients. METHODS: Retrospective data of RT-PCR confirmed hospitalized severe COVID-19 patients (total: n = 175 patients, including diabetic subset: n = 102) were analyzed. Clinically applicable cut-offs were derived using receiver operating characteristic (ROC) curve analysis for calculated total osmolality, eGFR, and D-dimer, and their correlations were studied. RESULTS: Among 175 severe COVID-19 patients, a significant association with mortality was seen with respect to calculated total osmolality (p < 0.001), eGFR (p < 0.001), and D-dimer (p < 0.001). In the total cohort, applicable cut-offs based on ROC curve in predicting outcome were, for total osmolality 299 mosm/kg (area under the curve (AUC)-0.773, odds ratio (OR)-1.09), eGFR 61.5 ml/min/m2 (AUC-0.789, OR-0.96), D-dimer 5.13 (AUC-0.814, OR-2.65) respectively. In diabetic subset, the cut-offs for total osmolality were 298 mosm/kg (AUC-0.794, OR-1.12), eGFR 44.9 ml/min/m2 (AUC-0.774, OR-0.96) and D-dimer 1.59 (AUC-0.769, OR-1.52) respectively. CONCLUSIONS: Applicable cut-offs for calculated total plasma osmolality, eGFR, and D-dimer predicts clinical outcome in severe COVID-19 with and without diabetes. Correlation studies validated calculated total osmolality as a marker of the combined effect of fluid and metabolic imbalance, compromised renal function and hypercoagulability.


Asunto(s)
COVID-19/diagnóstico , Tasa de Filtración Glomerular/fisiología , Plasma/química , Biomarcadores/sangre , Coagulación Sanguínea/fisiología , COVID-19/sangre , COVID-19/fisiopatología , COVID-19/terapia , Estudios de Cohortes , Complicaciones de la Diabetes/sangre , Complicaciones de la Diabetes/diagnóstico , Complicaciones de la Diabetes/fisiopatología , Complicaciones de la Diabetes/terapia , Femenino , Productos de Degradación de Fibrina-Fibrinógeno/análisis , Productos de Degradación de Fibrina-Fibrinógeno/metabolismo , Humanos , India , Masculino , Persona de Mediana Edad , Concentración Osmolar , Admisión del Paciente/estadística & datos numéricos , Pronóstico , Estudios Retrospectivos , Factores de Riesgo , Índice de Severidad de la Enfermedad , Trombosis/sangre , Trombosis/diagnóstico , Trombosis/etiología , Trombosis/fisiopatología , Equilibrio Hidroelectrolítico/fisiología
2.
Diabetes Metab Syndr ; 15(3): 739-745, 2021.
Artículo en Inglés | MEDLINE | ID: covidwho-1157247

RESUMEN

BACKGROUND AND AIMS: COVID-19 pandemic has strained the health infrastructure globally, providing an opportunity to identify cost-effective biomarkers. We aimed to identify simple hematological prognostic markers in hospitalized severe COVID-19 patients with and without diabetes. METHODS: Retrospective study of RT-PCR confirmed hospitalized severe COVID-19 patients (total: n = 154 patients, including diabetic subset n = 57) were analyzed. Clinically applicable cut-offs were derived using receiver operating characteristic (ROC) curve analysis for total leucocyte count (TLC), absolute neutrophil count (ANC), neutrophil lymphocyte ratio (NLR), and derived neutrophil lymphocyte ratio (dNLR) in order to prognosticate the outcome. RESULTS: Among 154 severe COVID-19 patients, significant association with mortality was seen with respect to TLC(p < 0.001), ANC (p < 0.001), NLR(p < 0.001) and dNLR(p < 0.001). In the total cohort, applicable cut-offs based on ROC curve in predicting outcome were, for TLC 8950 cells/mm3 (area under curve (AUC)-0.764, odds ratio (OR)-7.53), ANC 7679 cells/mm3 (AUC-0.789, OR-8.14), NLR 5.13 (AUC-0.741, OR-4.77), dNLR 3.44 (AUC -0.741, OR-4.43) respectively.In diabetic subset, the cut-offs for TLC was 8950 cells/mm3 (AUC -0.762, OR-14.9), ANC 6510 cells/mm3 (AUC -0.773, OR-16.8), NLR 5.13(AUC -0.678, OR-6) and dNLR 3.25(AUC -0.685, OR-4.7) respectively. CONCLUSIONS: In severe COVID-19 patients irrespective of diabetes, a simple, applicable total leucocyte count cut-off, 8950 cells/mm3 , together with easily derived cut-offs for ANC, NLR, dNLR may serve as cost-effective prognosticators of clinical outcome. A normal TLC may be misleading in the intensive care and the above applicable cut-off for TLC serves as an early warning tool for high-risk identification and better in-hospital management. Even with similar or lower cut-offs, diabetics had a higher mortality.


Asunto(s)
Biomarcadores/sangre , COVID-19/diagnóstico , Complicaciones de la Diabetes/diagnóstico , Pruebas Hematológicas , Hospitalización , Adulto , Anciano , Biomarcadores/análisis , COVID-19/complicaciones , COVID-19/epidemiología , COVID-19/patología , Estudios de Cohortes , Análisis Costo-Beneficio , Complicaciones de la Diabetes/epidemiología , Complicaciones de la Diabetes/patología , Femenino , Pruebas Hematológicas/economía , Pruebas Hematológicas/estadística & datos numéricos , Humanos , India/epidemiología , Recuento de Leucocitos/economía , Recuento de Leucocitos/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Pandemias , Evaluación del Resultado de la Atención al Paciente , Pronóstico , Estudios Retrospectivos , SARS-CoV-2 , Índice de Severidad de la Enfermedad , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA